Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Novel Insights into Idiopathic Pulmonary Fibrosis: Tvardi Therapeutics Advances with Promising Phase 2 Trial Results for TTI-101In the ever-evolving landscape of therapeutics for fibrotic diseases, Tvardi Therapeutics,...
Oct 13, 2025
• Major Pharmaceutical Preparations Industry
Business Update
Chart N
